| Bioactivity | ML404 (Compound 38) is an inhibitor of the mitochondrial permeability transition pore (mtPTP), which can suppress mitochondrial swelling (EC50=4.9 nM) and only disrupts mitochondrial coupling (an adverse effect) at concentrations > 100 μM. ML404 can be utilized in research related to multiple sclerosis (MS), amyotrophic lateral sclerosis (ALS), Alzheimer's disease (AD), muscular dystrophies (MD), myocardial infarction, and stroke[1]. |
| CAS | 1826026-00-9 |
| Formula | C17H13ClN2O3 |
| Molar Mass | 328.75 |
| Transport | Room temperature in continental US; may vary elsewhere. |
| Storage | Please store the product under the recommended conditions in the Certificate of Analysis. |
| Reference | [1]. Sileikyte J, et al. Small molecules targeting the mitochondrial permeability transition[J]. Probe Reports from the NIH Molecular Libraries Program [Internet], 2015. [2]. Roy S, et al. Discovery, synthesis, and optimization of diarylisoxazole‐3‐carboxamides as potent inhibitors of the mitochondrial permeability transition pore[J]. ChemMedChem, 2015, 10(10): 1655-1671. |